Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
Key Highlights
- ➤Visara secures exclusive worldwide VIS-102 rights, excluding Greater China
- ➤VIS-102 Phase 1b highest dose achieved 50% complete corneal healing
- ➤Vehicle control achieved 14% complete corneal healing at Week 4
- ➤Hiteck receives upfront, milestone payments and tiered net-sales royalties
- ➤Visara expands ophthalmology pipeline beyond retinal vascular disease into neurotrophic keratitis
Expert Statements
Jeffrey Nau, President and Chief Executive Officer of Visara
“Patients with neurotrophic keratitis face a serious, sight-threatening disease, and the practical demands of treatment can place a significant burden on patients and their caregivers.”
Jeffrey Nau, President and Chief Executive Officer of Visara
“VIS-102 was designed to address that directly.”
Jeffrey Nau, President and Chief Executive Officer of Visara
“We believe its molecular architecture and refrigerated, ready-to-use format could simplify care for patients and providers.”
Jeffrey Nau, President and Chief Executive Officer of Visara
“VIS-102 is a compelling addition to our pipeline as we build a company addressing unmet needs across the front and back of the eye.”
Srishti Gupta, Chief Executive Officer of NovaBridge
“The expansion of Visara’s pipeline illustrates how we are applying the NovaBridge model to build focused franchises around differentiated innovation.”
Srishti Gupta, Chief Executive Officer of NovaBridge
“With VIS-102, Visara expands beyond retinal disease into a second area of significant unmet need.”
Srishti Gupta, Chief Executive Officer of NovaBridge
“We believe this is an important step in building Visara into a broader ophthalmology company and demonstrates the repeatability of the NovaBridge approach to creating long-term value.”
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2
Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage program, expanding the Company's ophthalmology portfolio beyond retinal vascular disease into ocular surface disease
Get started
Create a free account to read the full story.